Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

August 31, 2015

Conditions
Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
Interventions
DRUG

Lenalidomide

Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression

Trial Locations (24)

13915

AP-HM Hôpital Nord, Marseille

21079

CHU de Dijon, Le Bocage, Dijon

25030

CHU Besançon, Hôpital Saint-Jacques, Besançon

31059

CHU de Toulouse Hôpital Larrey, Toulouse

33604

CHU de Bordeaux Hôpital du Haut Lévèque, Pessac

34295

CHRU de Montpellier Hôpital Saint-Eloi, Montpellier

37044

CHU de Tours- Hôpital Trousseau, Tours

38043

CHU de Grenoble, Grenoble

44093

CHU de Nantes, Hôtel Dieu, Nantes

51092

CHU de Reims, Hôpital Robert Debré, Reims

59037

CHU de Lille Hôpital Claude Huriez, Lille

63003

CHU de Clermont-Ferrand, Estaing, Clermont-Ferrand

69373

Centre Léon Bérard, Lyon

69450

CHU Lyon Sud, Pierre-Bénite

75475

AP-HP- Hôpital Saint Louis, Paris

75679

AP-HP Groupe hospitalier Cochin, Paris

75877

AP-HP Groupe hospitalier Bichat - Claude Bernard, Paris

75970

AP-HP Hôpital Tenon, Paris

76031

CHU de Rouen, Hôpital Charles Nicolle, Rouen

80054

CHU Amiens, Hôpital Sud, Amiens

92104

AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt

93009

AP-HP Hôpital Avicenne, Bobigny

94010

AP-HP Hôpital Henri Mondor, Créteil

06202

CHU de Nice Groupe hospitalier l'Archet, Nice

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT01556035 - Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma | Biotech Hunter | Biotech Hunter